Cancer Prevention
100 Most Popular
Most Popular Under $25

Insys Therapeutics

$4.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.13 (2.83%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell INSY and other stocks, options, ETFs, and crypto commission-free!

About

INSYS Therapeutics, Inc. operates as a pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing commercial pharmaceutical products that include Subsys, a proprietary sublingual fentanyl spray for BTCP in opioid-tolerant adult patients; and Syndros, a proprietary orally administered liquid formulation of dronabinol for the treatment of CINV and anorexia associated with weight loss in patients with AIDS. Read More The company was founded by John N. Kapoor on June 15, 1990 and is headquartered in Chandler, AZ.

Employees
226
Headquarters
Chandler, Arizona
Founded
1990
Market Cap
341.41M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
763.35K
High Today
$4.78
Low Today
$4.46
Open Price
$4.61
Volume
208.05K
52 Week High
$11.65
52 Week Low
$3.35

Collections

Cancer Prevention
100 Most Popular
Most Popular Under $25
Health
Pharmaceutical
Biotechnology
Therapy
Technology

News

Yahoo FinanceMar 14

Insys Plunges on Auditor's Concern About Insufficient Funds

Insys Therapeutics, Inc. INSY announced in its 10-K filing with Securities Exchange Commission that the company’s auditor has raised concerns about its ability to continue operations. Shares of the company plunged more than 25% on Mar 13 following the filing. However, shares of Insys have increased 21.4% so far this year compared with the industry’s rally of 11.9%. Scroll to continue with content Ad In fact, the auditor stated that the company may not be able to meet its ongoing legal expenses and obliga...

2,231
Markets InsiderMar 14

5 Top Losers In Healthcare Sector (SIEN, INSY, HIIQ...)

(RTTNews) - The following are some of the pharma/biotech stocks that posted the biggest percentage decline today. 1. Sientra Inc. (SIEN) Lost 28.65% to close Wednesday's (Mar.13) trading at $8.12. News: The Company reported financial results for the fourth quarter and full year ended December 31, 2018. Net loss for the fourth quarter of 2018 widened to $24.6 million or $0.86 per share from $17.8 million or $0.92 per share for the same period in 2017. Total net sales for the fourth quarter of 2018 were $...

1,188
The Motley FoolMar 13

Why Express, Roku, and Insys Therapeutics Slumped Today

The stock market has been moving sharply higher lately, and Wednesday was no exception. A 0.6% gain for the Dow Jones Industrial Average matched well with similar-sized jumps in other major indexes, with investors taking comfort from encouraging readings on the macroeconomic front. Yet even though much of the market continued to build on gains from earlier in the week, some stocks weren't able to participate in the rally. Express (NYSE:EXPR), Roku (NASDAQ:ROKU), and Insys Therapeutics (NASDAQ:INSY) were amo...

4,359

Earnings

-$0.61
-$0.40
-$0.18
$0.03
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.